Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ESMO
Filter by Topic
ESMO 2010 Conference
ESMO 2011 Conference
ESMO 2012 Conference
ESMO 2013 Conference
ESMO 2014 - Gastrointestinal and Head & Neck Cancer
ESMO 2014 - Immuno-Oncology
ESMO 2014 - Prostate Cancer
ESMO 2014 Highlights
ESMO 2016
ESMO 2017 Highlights
ESMO 2018
ESMO 2019
Head-to-Head Comparison: Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
By
Caroline Helwick
ESMO 2012 Conference
,
ESMO
October 2012, Vol 3, No 7
Vienna, Austria—In a head-to-head comparison of 2 treatments for metastatic renal-cell carcinoma (mRCC), pazopanib (Votrient) showed similar efficacy to sunitinib (Sutent), with a 1-month survival advantage for sunitinib, which was associated with fewer side effects and an increased quality of life (QOL), suggested Robert J. Motzer, MD, Professor of Medicine, Weill Medical College of Cornell University, and an attending physician at Memorial Sloan-Kettering Cancer Center, New York.
Read Article
High Economic Burden Associated with Thromboembolism in Patients with Cancer
ESMO 2012 Conference
,
ESMO
October 2012, Vol 3, No 7
A review of 34,000 patients with cancer in an insurance claims database showed that during the first 12 months after the diagnosis of cancer, the overall cost of developing venous thromboembolism (VTE) was approximately $100,000 per patient, reported Duke University researchers at the 2012 European Society for Medical Oncology.
Read Article
New Drugs for the Treatment of Prostate Cancer
By
Phoebe Starr
ESMO 2012 Conference
,
ESMO
October 2012, Vol 3, No 7
Vienna, Austria—Promising preliminary results for 2 novel prostate can-cer drugs—ODM-201 and OGX-427—were reported at the 2012 European Society for Medical Oncology Congress. Both drugs were studied for the treatment of castration-resistant prostate cancer (CRPC).
Read Article
Updated Data Confirm Survival Benefits with T-DM1 in Breast Cancer and with Regorafenib in Colon Cancer
By
Phoebe Starr
ESMO 2012 Conference
,
ESMO
October 2012, Vol 3, No 7
Vienna, Austria—The updated analyses of 2 major studies of drugs that were recently approved by the US Food and Drug Administration (FDA) confirm the benefits of trastuzumab emtansine (T-DM1) in patients with advanced HER2-positive breast cancer and of regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).
Read Article
Crizotinib Superior to Chemotherapy, Extends Median Survival in First Head-to-Head Trial
By
Audrey Andrews
ESMO 2012 Conference
,
ESMO
October 2012, Vol 3, No 7
Vienna, Austria—In the first head-to-head phase 3 clinical trial, the anaplastic lymphoma kinase (
ALK
) inhibitor crizotinib (Xalkori) proved more effective than standard chemotherapy with pemetrexed (Alimta) or docetaxel (Taxotere) as a second-line treatment for patients with non–small-cell lung cancer (NSCLC) and the
ALK
genetic abnormality.
Read Article
Continuation of Bevacizumab Beyond Progression Improves Outcome in Patients with Metastatic Colorectal Cancer
By
Caroline Helwick
ESMO 2012 Conference
,
ESMO
October 2012, Vol 3, No 7
Vienna, Austria—More support for the continuation of treatment with bevacizumab beyond disease progression in patients with metastatic colorectal cancer was reported at the 2012 European Society for Medical Oncology (ESMO) Congress, validating a small but growing body of previous data.
Read Article
Delivering Affordable, Evidence-Based Cancer Care in High-Income Countries
By
Caroline Helwick
ESMO 2011 Conference
,
ESMO
December 2011, Vol 2, No 7
A consortium of world cancer specialists, economists, and policymakers is tackling the issue of equitable cancer care in the face of rising cost of care in high-income countries.
Read Article
Thromboembolism after Chemotherapy Raises Healthcare Costs about 30%
By
Caroline Helwick
ESMO 2011 Conference
,
ESMO
December 2011, Vol 2, No 7
The development of venous thromboembolism (VTE) in patients with cancer has a significant impact in terms of morbidity and mortality and healthcare costs, according to a “real-world analysis” reported at the 2011 European Multi - disciplinary Cancer Congress.
Read Article
Predictive Biomarker for Bevacizumab May Be Emerging
By
Audrey Andrews
ESMO 2011 Conference
,
ESMO
December 2011, Vol 2, No 7
Read Article
Everolimus-Exemestane Combination Prolongs Remission by 4 Months in Metastatic Breast Cancer
By
Caroline Helwick
ESMO
,
ESMO 2011 Conference
October 2011, Vol 2, No 6
Stockholm, Sweden—The use of everolimus (Afinitor) together with the aromatase inhibitor exemestane (Aromasin) more than halved the risk for disease progression in patients with advanced breast cancer, adding an average of 4 disease-free months, investigators reported at the 2011 European Society for Medical Oncology European Multidisciplinary Cancer Congress.
Read Article
Page 7 of 8
1
2
3
4
5
6
7
8
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma